Abstract:Based on the fact that mAb 2F5 recognizing ELDKWA-epitope on the C-domain of HIV-1 gp41 has significant neutralization potency against 90% of the investigated viruses of African, Asian, American and European strains, we attempted to characterise immunogenicity of the ELDKWA-epitope on an epitope-vaccine, and to produce ELDKWA-epitope-specific monoclonal antibodies (mAb) induced by the epitope-vaccine. The C-domain peptide (P2) and the ELDKWA-tetramer peptide [C-(ELDKWAG)4] were conjugated with BSA or P24-EC (GPKEPFRDYVDRFYK, a peptide of HIV-1 gag-protein P24, proved to be a good carrier peptide to induce an immune response to the hapten on the conjugates[18])by different methods. After the vaccination course, two P2-BSA peptide-vaccines both induced a strong antibody response against the P2-peptide by about 1:12800–25600 dilution, and a weak antibody response against the ELDKWA-epitope (1:1600–3200). The P2-P24EC and P2 (conjugated with itself) peptide-vaccines could also induce a weak antibody response against the ELDKWA-epitope (1:1600–3200), while an rgpl60 subunit vaccine induced a very weak antibody response (1:400). Interestingly, the ELDKWA-tetramer epitope-vaccine [C-(ELDKWAGVBSA] could induce a strong antibody response against the ELDKWA-epitope (1:12800–25600), i.e. It increased the level of ELDKWA-antibody eight-fold, clearly better than the P2 peptide-vaccine, and much better than the rgp160 subunit vaccine, which indicates that the immunogenicities of the ELDKWA-epitope on the ELDKWA-tetramer peptide, the C-domain peptide and rgp160 are very different. These results suggest that the ELDKWA-epitope-vaccine may be a new strategy for inducing high levels of epitope-specific neutralizing antibodies against HIV- 1. Using hybridoma-technique, a mouse monoclonal antibody recognizing the ELDKWA-epitope on ELDKWA-peptide and C-domain peptide was produced by immunization with the C-(ELDKWAG)4-BSA epitope-vaccine, which indicates a new way to produce an epitope-specific mAb, namely immunization with epitope-vaccine instead of a natural or recombinant protein immunogen.

A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.

ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.

ELNKWA-epitope Specific Antibodies Induced by Epitope-Vaccine Recognize ELDKWA- and Other Two Neutralizing-Resistant Mutated Epitopes on HIV-1 Gp41

Characterization of Antibody Responses Against the 2F5 Epitope ELDKWA sing HIV-1 Env-Mediated Membrane Fusion and Neutralization Assays

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Neutralization of HIV-1 Primary Isolate by ELDKWA-specific Murine Monoclonal Antibodies.

Epitope-Vaccine Induces High Levels of Eldkwa-Epitope-Specific Neutralizing Antibody

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

The Neutralizing Epitope ELDKWA on HIV-1 Gp41: Genetic Variability and Antigenicity

Predefined GPGRAFY-Epitope-Specific Monoclonal Antibodies with Different Activities for Recognizing Native HIV-1 Gp120

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Recombinant Multi-Epitope Vaccine Induce Predefined Epitope-Specific Antibodies Against HIV-1

Repeated Epitope In The Recombinant Epitope-Peptide Could Enhance Eldkwa-Epitope-Specific Antibody Response

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Multifaceted Consequences of Anti-Gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions.

Epitope-focused Immunogens Against the CD4-binding Site of HIV-1 Envelope Protein Induce Neutralizing Antibodies Against Auto- and Heterologous Viruses

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1